Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 1 of 1 entries
Sorted by: Best Match Show Resources per page
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.

Medicine

Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y.
PMID: 29504984
Medicine (Baltimore). 2018 Jan;97(3):e9601. doi: 10.1097/MD.0000000000009601.

Phosphodiesterase type 5 (PDE5) inhibitors are recommended for patients with erectile dysfunction by American Urological Association and European Association Urology guidelines. However, recent researches have shown that PDE5 inhibitors may lead to increased melanoma risk. Thus, we aimed to...

Cite
Feng S, Zhou L, Liu Q, et al. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(3):e9601doi: 10.1097/MD.0000000000009601.
Feng, S., Zhou, L., Liu, Q., He, Q., Liao, B., Wei, X., Li, H., Wang, K., & Zhu, Y. (2018). Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine, 97(3), e9601. https://doi.org/10.1097/MD.0000000000009601
Feng, Shijian, et al. "Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis." Medicine vol. 97,3 (2018): e9601. doi: https://doi.org/10.1097/MD.0000000000009601
Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. Medicine (Baltimore). 2018 Jan;97(3):e9601. doi: 10.1097/MD.0000000000009601. PMID: 29504984; PMCID: PMC5779753.
Copy Download .nbib Format: NLM
Showing 1 to 1 of 1 entries